Metabolomics

Dataset Information

0

Lactate controls cancer stemness and plasticity through epigenetic regulation.


ABSTRACT:

Tumours arise from uncontrolled cell proliferation driven by mutations in genes that regulate stem cell renewal and differentiation. Intestinal tumours, however, retain some hierarchical organization, maintaining both cancer stem cells (CSCs) and cancer differentiated cells (CDCs). This heterogeneity, coupled with cellular plasticity enabling CDCs to revert to CSCs, contributes to therapy resistance and relapse. Using fluorescent metabolic and signalling reporters in human tumour organoids, combined with our machine learning-based cell tracker, CellPhenTracker, we simultaneously traced cell type specification, metabolic changes, and reconstructed cell lineage trajectories during tumour organoid development. Our findings reveal distinctive metabolic phenotypes in CSCs and CDCs. We find that lactate regulates tumour dynamics, suppressing CSC differentiation and inducing dedifferentiation into a proliferative CSC state. Mechanistically, lactate increases histone acetylation, epigenetically activating MYC. Given that lactate’s regulation of MYC depends on BRD4, targeting cancer metabolism combined with BET inhibitors emerges as a promising strategy to prevent tumour relapse. 

INSTRUMENT(S): Liquid Chromatography MS - negative - reverse phase

PROVIDER: MTBLS11849 | MetaboLights | 2025-05-28

REPOSITORIES: MetaboLights

Dataset's files

Source:
Action DRS
20201023_ESCG_024.raw Raw
20201023_ESCG_025.raw Raw
20201225_ES_064.raw Raw
20201225_ES_065.raw Raw
20201225_ES_066.raw Raw
Items per page:
1 - 5 of 199
altmetric image

Publications


Tumors arise from uncontrolled cell proliferation driven by mutations in genes that regulate stem cell renewal and differentiation. Intestinal tumors, however, retain some hierarchical organization, maintaining both cancer stem cells (CSCs) and cancer differentiated cells (CDCs). This heterogeneity, coupled with cellular plasticity enabling CDCs to revert to CSCs, contributes to therapy resistance and relapse. Using genetically encoded fluorescent reporters in human tumor organoids, combined wit  ...[more]

Similar Datasets

2022-08-02 | GSE209964 | GEO
2016-11-16 | GSE86518 | GEO
2018-08-13 | MTBLS541 | MetaboLights
2024-08-30 | GSE272850 | GEO
2025-09-12 | GSE295796 | GEO
2024-03-21 | GSE247880 | GEO
2017-01-10 | PXD004608 | Pride
2023-09-04 | GSE241932 | GEO
2023-09-04 | GSE242204 | GEO
2019-07-15 | GSE110868 | GEO